Knyga 2008 09_2 be EndNote.indd - Saulius Čaplinskas

Atsako į AIDS ir narkomaniją kontroversijos
134 Fonseca F, Gratacòs M, Escaramís G, et al. Response to methadone
maintenance treatment is associated with the MYOCD and GRM6
genes. Mol Diagn Ther 2010;14(3):171-8.
135 Peles E, Schreiber S, Naumovsky Y, Adelson M. Depression in methadone
maintenance treatment patients: rate and risk factors. Affect
Disord 2007; 99(1-3):213-20.
136 Murauskienė L, Gečienė I, Stankutė R. Farmakoterapijos metadonu
Lietuvoje vertinimas. Galutinė ataskaita (UNODC, 2011). Vilnius 2011;
p.100.
137 Hedrich D. European report on drug consumption rooms. European
Monitoring Centre for Drugs and Drug Addiction, Lisbon 2004. Prieiga
per internetą: http://www.emcdda.europa.eu/attachements.cfm/
att_2944_EN_consumption_rooms_report.pdf
138 The Report of the Independent Working Group on Drug Consumption
Rooms. Joseph Rowntree Foundation 2006. Prieiga per internetą:
http://www.jrf.org.uk/sites/files/jrf/WG-full.pdf
139 Kerr T, Kimber J, Debeck K, Wood E. The role of safer injection facilities
in the response to HIV/AIDS among injection drug users. Curr HIV/
AIDS Rep 2007;4(4):158-64.
140 Wood E, Kerr T, Tyndall MW, et al. Rates of HIV/AIDS care and
antiretroviral therapy response among active injection drug users.
Addiction 2007;102(9):1503-5.
141 Salmon AM, van Beek I, Amin J, Kaldor J, Maher L. The impact of a
supervised injecting facility on ambulance call-outs in Sydney,
Australia. Addiction 2010;105(4):676-83.
142 Milloy MJS, Kerr T, Tyndall M, Montaner J, Wood E Estimated Drug
Overdose Deaths Averted by North America’s First Medically-
Supervised Safer Injection Facility. PLoS ONE 2008; 3(10): e3351.
143 INCB. Report of the International Narcotics Control Board for 2009.
Vienna: United Nations 2009.
Prieiga per internetą: http://www.incb.org/pdf/annual-report/2009/
en/AR_09_English.pdf
144 Preventing HIV infection among infecting drag users in high-risk
countries. The national academies press. Waschington, d.c.2006.
145 Mazus A. AIDS prevention plans must reflect local values. Science 201;
332(6026):173.
146 Stein JA, Nyamathi A. Gender differences in behavioural and psychological
predictors of HIV testing and return for test results in a
high-risk population. AIDS Car 2000; 12 (3): 343–56.
147 Deren S, Shedlin M, Kang SY, Cortés DE. HIV risk and prevention
among Hispanic immigrants in New York: the salience of diversity.
Subst Use Misuse 2011; 46(2-3):254-63.
148 MacGrowan RJ, Brackbill RM, Rugg DL, et al. Sex, drugs and HIV
counseling and testing: a prospective study of behavior-change
among methadone-maintenance clients in New England. AIDS 1997;
11 (2): 229–35.
149 UNGASS Country progress report. Finland 2010. Prieiga per internetą:
http://www.unaids.org/en/dataanalysis/monitoringcountryprogress
/2010progressreportssubmittedbycountries/finland_2010_country_
progress_report_en.pdf
150 World Health Organisation. Policy Brief: Provision of sterile injecting
equipment to reduce HIV transmission. Geneva: 2004. Prieiga per internetą:
www.who.int/hiv/pub/advocacy/en/provisionofsterileen.pdf
151 McKeganey N, Bloor M, Robertson M, Neale J, MacDougall J. Abstinence
and Drug Abuse Treatment in Scotland: Results from the Drug
Outcome Research in Scotland Study. Glasgow: University of Glasgow
2005.
152 Hope VD, Judd A, Hickman M, et al. Prevalence of hepatitis C virus in
current injecting drug users in England and Wales: is harm reduction
working American Journal of Public Health 2001; 91(1): 38-42.
153 Health Protection Agency. Hepatitis C in the UK. London: Health
Protection Agency; 2009.
154 Bloor M, Neale J, McKeganey N. Persisting local variations in prevalence
of hepatitis C virus among Scottish problem drug users:
Results from an anonymous screening study. Drugs: education,
prevention and policy 2006; 13(2): 189–91.
155 Čaplinskas S. Narkotikų kontrolė: pragmatiška politika ir humanistinės
nuostatos. Acta medica Lituanica. 2001; suppl.6: 37-41.
156 Nacionalinės AIDS programos vertinimas. Lietuvos AIDS centras.
Prieiga per internetą: http://politika.osf.lt/visuomenes_sveikata/dokumentai/AIDS_programos_vertinimas.pdf
157 Narkotikų kontrolės departamentas prie Lietuvos Respublikos Vyriausybės.
Metinis pranešimas 2010. Europos narkotikų ir narkomanijos
stebėsenos centras. 2010.
158 Annual report. The state of the drugs problem in Europe. EMCDDA,
Lisbon 2009. Prieiga per internetą: http://www.emcdda.europa.eu/
publications/annual-report/2009
159 General Register Office for Scotland. Drug-Related Deaths in Scotland
in 2009. Edinburgh: General Register Office 2010. Prieiga per internetą:
http://www.gro-scotland.gov.uk/files2/stats/drug-related-deaths/
drd2009/drd2009.pdf
160 Office for National Statistics. Statistical Bulletin: Deaths related to
drug poisoning in England and Wales, 2009. Health and Care 2010.
Prieiga per internetą: http://www.ons.gov.uk
161 Health Protection Agency. Hepatitis C in the UK. London: Health
Protection Agency; 2009.
162 Gordon L, Tinsley L, Godfrey C, Parrott S. The economic and social
costs of Class A drug use in England and Wales, 2003/04. In: Singleton
N, Murray R, Tinsley L. eds. Measuring different aspects of problem
drug use: methodological developments. Home Office Online Report
16/06. 2006: 41-45. Prieiga per internetą: http://www.homeoffice.gov.
uk/rds/pdfs06/rdsolr1606.pdf
163 Casey J, Hay G, Godfrey C, Parrott S. Assessing the scale and impact of
illicit drug markets in Scotland. Scottish Government Social Research
2009. Prieiga per internetą: http://www.scotland.gov.uk/Resource/
Doc/287490/0087669.pdf
164 ACMD. Hidden Harm – Responding to the needs of children of
problem drug users. Advisory Council on the Misuse of Drugs 2003.
Prieiga per internetą:http: //www.homeoffice.gov.uk/publications/
agencies-public-bodies/acmd1/hidden-harm-fullview=Binary
165 Percy A, MdAlister S, Higgins K, McCrystal P, Thornton M. Response
consistency in young adolescents’ drug use self-reports: a recanting
rate analysis. Addiction 2005; 100 (2): 189-96.
166 Anstice S, Strike CJ, Brands B. Supervised methadone consumption:
Client issues and stigma. Substance Use and Misuse 2009;44(6):794–
808.
167 Palmateer N, Kimber J, Hickman M, Hutchinson S, Rhodes T, Goldberg
D. Evidence for the effectiveness of sterile injecting equipment
provision in preventing hepatitis C and human immunodeficiency
virus transmission among injecting drug users: a review of
reviews. Addiction 2010;105(5):844-59.
168 Abdulrahim D, Gordon D, Best D. Findings of a Survey of Needle
Exchanges in England. London: NTA; 2006.
169 Health Protection Agency. Anthrax: information on 2010 outbreak.
London: HPA 2005. Prieiga per internetą: http://www.
hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/Anthrax/
AnthraxOutbreakInformation/
170 Caplinskas S, Strujeva O, Caplinskiene I. HIV outbreak in prison followup
. 10th European AIDS conference, EACS, Dublin, Ireland, Nov 17-20,
2005: abstract. [Dublin, 2005]: 152-53.
171 Nadelmann E. Progressive Legalizers, Progressive Prohibitionists
and the Reduc tion of Drug-related Harm. In: Heather N, Wodak
A, Nadelmann E., O’Hare P. (ed): Psychoactive Drugs and Harm
Reduction: From Faith to Science. London: Whurr Publishers, 1993:
35–48.
172 Kad ir terminologijos pasikeitimas.
173 Advisory Council on the Misuse of Drugs. AIDS and drug misuse: part
one. London: Department of Health and Social Security. 1988.
174 EM CDDA 2011 m. metinė ataskaita: narkotikų problema Europoje.
Europos Sąjungos leidinių biuras, Liuksemburgas, 2011; p.38.
66